Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
Pharma giant targets new standards of care
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
The company plans to submit the vaccine for regulatory review
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
